Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest

 Grifols and Brookfield said they aren't in takeover talks, after a media report indicated the investment company had resumed discussions with the Grifols family--which controls the Spanish pharmaceutical company--about a possible deal.

"Brookfield is not, and has not been, in discussions with the company's board of directors with respect to a potential transaction," Brookfield said.

The investor said it maintains a general dialogue with Grifols's reference shareholders, but said there is no update since it decided against making a bid for the company in November.

Grifols's board said separately that it "has no knowledge" of talks regarding another attempt by Brookfield to acquire the company.

The statements came after Spanish news website El Confidencial reported, citing unnamed sources, that Brookfield had resumed talks with the Grifols family over a possible deal.

Shares in Grifols traded 6% higher at 8.63 euros in European afternoon trading, paring back gains of as much as 15% earlier in the session, after both Grifols and Brookfield issued their statements.

https://www.morningstar.com/news/dow-jones/202504024228/grifols-brookfield-deny-takeover-talks-after-report-of-renewed-interest-update

US Senate committee opens review into Meta efforts to gain Chinese market access

 A U.S. Senate investigative subcommittee on Tuesday opened a review into efforts by Facebook parent Meta Platforms (NASDAQ:META) to gain access to the Chinese market and is seeking documents from the company.

Senator Ron Johnson, who chairs the Permanent Subcommittee on Investigations, joined by Senator Richard Blumenthal, the top Democrat, and Senator Josh Hawley, asked Meta CEO Mark Zuckerberg about allegations that it worked to build censorship tools for the Chinese Communist Party as part of its attempt to gain entry to the Chinese market, according to a letter seen by Reuters.

The senators want Meta to disclose extensive records including all company communications or records of meetings with Chinese government officials since 2014. They want Meta to do this by April 21.

The senators cited reports in the recently published book "Careless People," by former Facebook executive Sarah Wynn-Williams, that in 2014 the company allegedly developed a "three-year plan" to gain access to the Chinese market. The initiative was code-named "Project Aldrin," the book said.

The senators’ letter said the "accounts are corroborated by internal records documenting these efforts reviewed by the Subcommittee."

A Meta spokesperson rejected the claims.

"This is all pushed by an employee terminated eight years ago for poor performance. We do not operate our services in China today. It is no secret we were once interested in doing so as part of Facebook’s effort to connect the world," the company said. "We ultimately opted not to go through with the ideas we’d explored, which Mark Zuckerberg announced in 2019."

https://www.investing.com/news/stock-market-news/us-senate-committee-reviews-meta-efforts-to-gain-access-to-chinese-market-3961470

Microsoft-Backed ChatGPT Surges Past 150 Million Users After Viral AI Feature

 ChatGPT just had one of its biggest weeks ever. The Microsoft (NASDAQ:MSFT)-backed AI tool broke records after it rolled out its new Ghibli effect, a feature that lets users generate images in the style of Studio Ghibli's iconic animation. The viral feature helped push weekly active users past 150 million the highest so far this year.

OpenAI CEO Sam Altman shared the surge on X, saying the platform added a million users in just one hour. That's a big leap compared to ChatGPT's early days, when it took five days to reach the same milestone.

The growth wasn't just in users. Downloads of the app rose 11% week-over-week, while in-app purchases climbed 6%, according to SensorTower data cited by Reuters. That momentum also led to server strain, with outages and delays across the platform. Altman acknowledged the pressure, warning that future releases might be slower as the company works through capacity challenges.

The chatbot is now generating around $415 million in monthly revenue up 30% from late last year and OpenAI is reportedly raising $40 billion in fresh funding, which would bring its valuation to $300 billion.

https://au.finance.yahoo.com/news/microsoft-backed-chatgpt-surges-past-134101675.html

Breakthrough in Parkinson's Treatment: AC Immune's Phase 2 Trial Reveals 20-Fold Antibody Boost

 AC Immune (NASDAQ: ACIU) has reported positive interim results from its Phase 2 VacSYn clinical trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease. The treatment has demonstrated significant efficacy, producing anti-α-synuclein antibody levels over 20-fold higher than placebo after 4 immunizations.

The trial's Part 1 involves over 30 patients randomized at a 3:1 ratio (treatment:placebo). Key findings show that antibody responses were effectively induced at week 6 after 2 immunizations and were further enhanced with additional doses. The treatment has shown a favorable safety profile with no serious adverse events reported, with only mild side effects including injection site reactions and headaches.

Based on upcoming interim results in 2025, including pharmacodynamic and biomarker data, the company may proceed with Part 2 of the trial, expanding to up to 150 patients. This phase will evaluate disease progression through motor and non-motor symptoms, along with digital, imaging, and fluid biomarkers.

https://www.stocktitan.net/news/ACIU/ac-immune-reports-further-positive-interim-results-from-phase-2-xi5i1fhdfsbw.html

Cytokinetics stock rises following competitor's trial results

 Shares of Cytokinetics (NASDAQ: NASDAQ:CYTK) climbed 11% after Edgewise Therapeutics reported results for its treatment of hypertrophic cardiomyopathy (HCM), which led to a 28% decline in Edgewise’s stock. The market movement reflects investor sentiment on the potential implications for Cytokinetics’ own HCM treatment, aficamten.

Morgan Stanley analyst Maxwell Skor maintained an Overweight rating and a price target of $67.00 on Cytokinetics, citing the differentiation in safety profiles between Cytokinetics’ aficamten and Edgewise Therapeutics’ treatment. In his analysis, Skor noted that Edgewise’s EDG-7500 and Cytokinetics’ aficamten target the same condition but through different mechanisms. Skor highlighted that aficamten did not show a difference in atrial fibrillation incidence compared to placebo, based on an integrated safety analysis across multiple studies.

RBC analyst Leonid Timashev provided a mixed perspective on the readthrough from Edgewise’s data to Cytokinetics. While he acknowledged the strong efficacy data from Edgewise, he pointed out potential concerns regarding atrial fibrillation that could align the drug’s use profile more closely with cardiac myosin inhibitors (CMIs), potentially eroding a convenience advantage. However, Timashev continues to favor Cytokinetics, expecting the company to leverage a more convenient profile to drive significant sales and establish a strong market position ahead of Edgewise’s launch.

The direct quote from Morgan Stanley’s Skor reinforces the positive outlook: "Overall, we expect CTYK to be up 5%+ on aficamten’s differentiated safety profile."

Investors appear to be responding to these analyses, with Cytokinetics’ stock reacting positively to the comparative safety data and the potential for its HCM treatment to stand out in the market. The developments underscore the competitive nature of the biotechnology sector, where clinical trial results can significantly impact the market dynamics and the perceived value of treatments in development.

https://www.investing.com/news/stock-market-news/cytokinetics-stock-rises-following-competitors-trial-results-93CH-3962966

Allakos agrees to Concentra Biosciences acquisition

 Allakos Inc. (NASDAQ:ALLK), a biotechnology firm focused on developing antibodies to treat allergic and inflammatory diseases, has announced a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Allakos for $0.33 per share in cash, representing a 50% premium to the current stock price of $0.22. The offer comes as Allakos shares have declined 82.5% over the past year, trading near their 52-week low. According to InvestingPro analysis, the stock has been showing signs of oversold conditions.

The Board of Directors of Allakos has unanimously approved the transaction, deeming it in the best interests of Allakos shareholders. A tender offer is set to commence by April 15, 2025, to acquire all outstanding Allakos common stock, with the merger expected to finalize in May 2025. The offer price falls within the current analyst target range of $0.30 to $0.40 per share. InvestingPro data reveals that while the company maintains a strong current ratio of 4.81, it has been rapidly burning through its cash reserves.

Allakos shareholders holding approximately 8.07% of the common stock have committed to tendering their shares and supporting the merger through signed support agreements. The completion of the tender offer is contingent upon several conditions, including a majority of the outstanding shares being tendered, the availability of at least $35.5 million in cash at closing (net of costs and liabilities), and other customary closing conditions.

https://www.investing.com/news/company-news/allakos-agrees-to-concentra-biosciences-acquisition-93CH-3962620

Organovo's Financial Update: $11.3M Cash Reserve Plus $55M Potential Milestone Payments

 Organovo Holdings (NASDAQ: ONVO), a clinical stage biotechnology company focused on IBD treatments, has provided a financial and listing status update. The company reported preliminary unaudited cash and cash equivalents of approximately $11.3 million as of March 31, 2025, with net cash utilization of $2.0-$2.2 million in Q4 FY2025.

The company expects to maintain its Nasdaq Capital Market listing as its stock has traded above the required $1.00 minimum bid price since March 21, 2025. Full fiscal Q2 results are expected between June 9-13, 2025.

Additionally, Organovo anticipates receiving a $5 million milestone payment within the next 12 months upon the start of a Phase 2 clinical trial for its recently sold FXR agonist. The company could receive up to $50 million in total future milestone payments related to this asset.

https://www.stocktitan.net/news/ONVO/organovo-provides-update-on-cash-and-nasdaq-continued-listing-2yusfg4sqsjh.html